ENSEMBLE trial
E241392
The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
All labels observed (1)
| Label | Occurrences |
|---|---|
| ENSEMBLE trial canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T2190766 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: ENSEMBLE trial Context triple: [Janssen COVID-19 Vaccine, clinicalTrialPhase3, ENSEMBLE trial]
-
A.
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
B.
ENGAGE (Study 301)
ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
-
C.
ARRAY Alliance
ARRAY Alliance is a nonprofit organization and social impact collective founded by filmmaker Ava DuVernay to advance racial and gender equity in the entertainment industry and beyond.
-
D.
Euroradar consortium
The Euroradar consortium is a multinational industrial partnership responsible for designing and producing advanced airborne radar systems for modern fighter aircraft.
-
E.
Cordis
Cordis is a medical device company best known for developing and manufacturing cardiovascular and endovascular products such as stents and catheters.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: ENSEMBLE trial Target entity description: The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
-
A.
EMERGE (Study 302)
EMERGE (Study 302) is a pivotal Phase 3 clinical trial designed to evaluate the efficacy and safety of the Alzheimer’s disease drug aducanumab (Aduhelm) in patients with early-stage Alzheimer’s.
-
B.
ENGAGE (Study 301)
ENGAGE (Study 301) is a large Phase 3 clinical trial designed to evaluate the efficacy and safety of the anti-amyloid monoclonal antibody aducanumab (Aduhelm) in patients with early Alzheimer’s disease.
-
C.
ARRAY Alliance
ARRAY Alliance is a nonprofit organization and social impact collective founded by filmmaker Ava DuVernay to advance racial and gender equity in the entertainment industry and beyond.
-
D.
Euroradar consortium
The Euroradar consortium is a multinational industrial partnership responsible for designing and producing advanced airborne radar systems for modern fighter aircraft.
-
E.
Cordis
Cordis is a medical device company best known for developing and manufacturing cardiovascular and endovascular products such as stents and catheters.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
COVID-19 vaccine trial
ⓘ
Phase 3 clinical trial ⓘ clinical trial ⓘ |
| allocation | 1:1 vaccine to placebo ⓘ |
| design |
double-blind
ⓘ
placebo-controlled ⓘ randomized ⓘ |
| developerOfInvestigationalProduct | Ad26.COV2.S ⓘ |
| doseRegimen | single dose ⓘ |
| endpoint |
COVID-19–related death
ⓘ
COVID-19–related hospitalization ⓘ moderate to severe COVID-19 ⓘ severe COVID-19 ⓘ virologically confirmed COVID-19 ⓘ |
| evaluatedVaccine |
Janssen single-dose COVID-19 vaccine
ⓘ
linked to:
Janssen COVID-19 Vaccine
|
| geographicScope | multinational ⓘ |
| includedRegion |
Africa
ⓘ
Asia ⓘ Europe ⓘ North America ⓘ South America ⓘ |
| interventionModel | parallel assignment ⓘ |
| masking |
care provider
ⓘ
investigator ⓘ outcomes assessor ⓘ participant ⓘ |
| phase | Phase 3 ⓘ |
| population | adults 18 years of age and older ⓘ |
| primaryObjective | evaluate efficacy of a single dose of Ad26.COV2.S in preventing moderate to severe COVID-19 ⓘ |
| regulatoryUse | supported emergency use authorization applications ⓘ |
| relatedTo | Janssen COVID-19 Vaccine ⓘ |
| routeOfAdministration | intramuscular injection ⓘ |
| safetyAssessment |
adverse events of special interest
ⓘ
local adverse events ⓘ medically attended adverse events ⓘ serious adverse events ⓘ systemic adverse events ⓘ |
| safetyPopulation | all participants who received at least one dose of study vaccine or placebo ⓘ |
| scope | global ⓘ |
| secondaryObjective |
evaluate efficacy in preventing severe COVID-19
ⓘ
evaluate safety of Ad26.COV2.S ⓘ |
| sponsor |
Janssen Pharmaceuticals
ⓘ
Janssen Vaccines & Prevention B.V. ⓘ
linked to:
Janssen Pharmaceuticals
|
| sponsorParentCompany | Johnson & Johnson ⓘ |
| startYear | 2020 ⓘ |
| targetDisease |
COVID-19
ⓘ
linked to:
COVID-19 pandemic
|
| targetPathogen | SARS-CoV-2 ⓘ |
| trialType | interventional ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: ENSEMBLE trial Description of subject: The ENSEMBLE trial was a large, global Phase 3 clinical study designed to evaluate the safety and efficacy of Janssen’s single-dose COVID-19 vaccine in preventing SARS-CoV-2 infection and severe disease.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.